Catalog # 10-2120
Bortezomib
CAS# 179324-69-7
N-(2-Pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
MG-341, PS-341
Lot # X102736

Potent and selective proteasome inhibitor (K_{i}=0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC_{50}=7 nM). Inhibits TNFα synthesis and FGF-induced angiogenesis. Clinically useful agent for treatment of multiple myeloma.\(^3\) Shows promise in the treatment of neurodegenerative diseases in which low-expressing proteins such as IKAP/hELP1 in familial dysautonomia are preserved.\(^4\)


1) Adams et al. (1999), Proteasome inhibitors: a novel class of potent and effective antitumor agents; Cancer Res., 59 2615
2) Williams et al. (2003), Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts; Mol. Cancer Ther., 2 835
3) Richardson et al. (2003), Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers; Cancer Control, 10 361
4) Herve and Ibrahim (2017), Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia; Neurobiol. Dis., 103 113

**PHYSICAL DATA**

Molecular Weight: 384.25
Molecular Formula: C_{19}H_{25}BN_{4}O_{4}
Purity: >98% by HPLC
NMR: (Conforms)
Solubility: DMSO (up to 50 mg/ml), Ethanol (up to 35 mg/ml)
Physical Description: White solid
Storage and Stability: Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in DMSO and ethanol may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.
Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462
www.focusbiomolecules.com